Should We Measure CSF Complement Levels in Patients With MOGAD?

Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200302. doi: 10.1212/NXI.0000000000200302. Epub 2024 Aug 12.

Authors

Carson E Moseley¹, Scott S Zamvil¹

Affiliation

¹ From the Department of Neurology (C.E.M.), Weill Institute for Neurosciences; Department of Neurology (S.S.Z.), Weill Institute for Neurosciences, and Program in Immunology, University of California, San Francisco.

No abstract available

Publication types

Editorial

MeSH terms

Biomarkers / blood
Biomarkers / cerebrospinal fluid
Complement System Proteins* / cerebrospinal fluid
Humans
Myelin-Oligodendrocyte Glycoprotein / cerebrospinal fluid
Myelin-Oligodendrocyte Glycoprotein / immunology

Substances

Complement System Proteins
Myelin-Oligodendrocyte Glycoprotein
Biomarkers

Grants and funding

R01 AI170863/AI/NIAID NIH HHS/United States